garyg

Today we announced an expanded collaboration with both @moderna_tx and @Merck to support the potential commercialization of intismeran autogene, a novel individualized neoantigen therapy. Tempus will deliver advanced NGS sequencing and sample collection workflows, combining our clinical infrastructure with mRNA innovation to help bring personalized cancer vaccines to patients at scale. Read on: tempus.com/news/pr/tempus-an…

We’re excited to announce the expansion of our care pathway intelligence platform, Tempus Next, into breast cancer. The platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients. Learn more: tempus.co/3GqkikA

We’re excited to be in Madrid at #ESMO23 presenting five abstracts that demonstrate our advanced genomic sequencing capabilities, which contribute to more informed, data-driven patient care in oncology. Attend one of the poster or learn more here: tempus.co/3FlPcWV

We’re excited to be on-site at #ASCO23 exhibiting 20 abstracts, including research that demonstrates how the tumor-normal match feature of our xT assay may detect germline alterations and inform patient care across different cancer types. Learn more: tempus.co/3oDWMHS

Tempus One is a first-of-its-kind, chat-enabled AI platform that provides clinicians access to patient insights directly at their fingertips. Gain early access by signing up to meet w/ our team at #ASCO23 or schedule time to get provisioned here: tempus.co/40BpyFZ

#NEWS: We’re collaborating with @GSK on a PHASE II study to evaluate the efficacy and safety of ZEJULA (niraparib) for patients with advanced or metastatic solid tumors and a germline or somatic PALB2 mutation. The study is now open, and you can learn more here.

For #WorldCancerDay, help us spread awareness about how #GenomicSequencing can guide cancer treatment decisions and improve patient outcomes by sharing this post, and learn more about our portfolio of precision oncology solutions here: tempus.co/2Moi4G4.

During #COVID19, "Tempus is leveraging its many resources to ensure that [oncology] research not only continues, but that investigators have seamless access to the highest quality data,” - Kim Blackwell, Tempus Chief Medical Officer. Read more: bit.ly/3eDohGJ.

This summer, we're launching two new precision medicine-driven oncology tests; Tempus|HRD, which identifies a patient’s homologous recombination deficiency (HRD) status, and Tempus|TO, which predicts the tissue of origin (TO) for tumors: bit.ly/3gFESLZ. #ASCO20

Read why we believe enlisting big data in the war against cancer is critical. usnews.com/news/healthcare-o…